Immunogenicity and Safety of Hepatitis A Among People Aged 18-50 Years Old

Conditions: Hepatitis A Interventions: Biological: Healive (hepatitis A vacine(human diploid cell), inactivated) Sponsors: Sinovac Biotech Co., Ltd; Liaoning Center for Disease Control and Prevention Not yet recruiting

https://clinicaltrials.gov/study/NCT06058416

Source: ClinicalTrials.gov - September 28, 2023 Category: Research Source Type: clinical trials

More News: Biotechnology | Centers for Disease Control and Prevention (CDC) | Hepatitis | Hepatitis A | Research